Responding to Disappointing Clinical Trial Results
Dear Clients,
We are pleased to share our client update on responding to disappointing clinical trial results.
The update considers several strategic paths that life sciences companies may pursue following missed clinical endpoints or unfavorable interim data, including focusing on a defined patient population, continuing development in other indications, adapting an ongoing development plan, or reallocating resources to higher priority programs.
It also highlights practical considerations for biotechnology, pharmaceutical and medical device companies relating to clinical strategy, contractual flexibility, data access, financing, partnering and communications.
As always, the team at Agmon with Tulchinsky remains at your disposal.
Practices:
More Relevant Media
20.05.2026
Cell Therapy in Non Muscle Invasive Bladder Cancer: A Development Life Sciences Companies Should Watch
Client updates
26.07.2026
EU Life Sciences Reforms: The Evolving Landscape for Clinical Development, Market Access and Manufacturing
Client updates
15.10.2024
EU AI Act and its Impact on Israeli Companies in the Pharma and Medical Device Sector
Publications
29.12.2025
EU Commission’s Medical Devices Regulation Simplification Proposal and EUDAMED Mandatory Modules Timeline
Client updates